| Status: Medicine does not meet criteria for AWMSG assessment | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease |
|
Medicine details |
|
| Medicine name | cipaglucosidase alfa |
| Formulation | intravenous infusion |
| Reference number | 4880 |
| Indication | In conjunction with miglustat for the long-term treatment of adult symptomatic patients with confirmed diagnosis of late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) who have received enzyme replacement therapy with alglucosidase alfa for ≥ 2 years |
| Company | Amicus Therapeutics UK Ltd |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 30/01/2023 |
| NICE guidance | TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease |